Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

A vaccine consisting of an inactivated, Modified Vaccinia Ankara (MVA) viral vector encoding three herpes virus cytomegalovirus (CMV) tumor-associated antigens (TAAs), including UL83 (pp65), UL123 (IE1) and UL122 (IE2), with potential immunostimulating activity. The viral peptides expressed after administration of the multi-peptide CMV-MVA vaccine, may stimulate the immune system to mount both cytotoxic T-lymphocyte (CTL) and helper T-cell responses against CMV-infected cells. This results in cell lysis and prevents viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants. (NCI Thesaurus)

YOU MAY ALSO LIKE

Multi-Institutional Clinical Trial

A clinical trial that is carried out at more than one medical institution.

Multi-institution Indicator

Specifies whether a study is designed to be conducted at more than one site concurrently.

Multi-Infarct Dementia

A common form of dementia caused by multiple cortical or subcortical cerebral infarctions.

Multi-epitope Melanoma Peptide Vaccine

A peptide cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates…

Multi-epitope Folate Receptor Alpha Peptide Vaccine

A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (FR alpha or FOLR1), including FR30, FR56, FR76,…

Multi-Drug Resistant Organism

A microorganism, often a bacterium, that is not susceptible to standard antimicrobial therapies.